Huisheng Bio completed 500 million yuan in Series A financing – FENQ
Summary
Today, Huisheng Bio has more than 200 people, rich experience in diabetes drug research and development, and a world-class professional R&D team. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical Holdings Group, said: Huisheng Bio is currently the only biopharmaceutical company in China that has achieved full product coverage in the field of diabetes and complications. Thanks for their strong support, This will enable Huisheng Biotechnology to continue its efforts in the field of biomedicine to benefit more patients with diabetes and complications.Jiang Li, Managing Director of China Life Equity Company, said: In recent years, the prevalence of diabetes has continued to rise, and it has become a major global challenge for individuals, families and society. The full product deployment of Sheng Bio in the field of diabetes drug research and development and the treatment of complications is fully optimistic about the future value of the company. The equity of China Life will continue to help Hui Sheng Bio to grow into a biomedical leader with comprehensive solutions for diabetes and complications, benefiting global diseases suffer.Dr.